p53-protein and Ki-67-antigen expression are both reliable biomarkers of prognosis in thick stage I nodular melanomas of the skin

Histopathology

Volumn 30, Issue 1, 1997, Pages 57-63

  Vogt, T ^a,c   Zipperer, K H ^a   Vogt, A ^a   Holzel D ^b   Landthaler, M ^a   Stolz, W ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c SIDNEY KIMMEL CANCER CENTER   (United States)

Author keywords

image analysis; Ki 67; malignant melanoma; p53; stereology

Indexed keywords

MONOCLONAL ANTIBODY KI 67; PROTEIN P53; TUMOR MARKER;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MELANOMA; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; SKIN CANCER; STEREOLOGY;

EID: 0031027691     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2559.1996.d01-558.x     Document Type: Article

References (29)

1. Ruiter DJ. Clinical and pathologic diagnosis, staging and prognostic factors of melanoma and management of primary disease. Curr. Opin. Oncol. 1992: 4; 357-367.
2. Vogt T, Stolz W, Hohenleutner U, Schiffner R, Landthaler M. Prognostic significance of DNA cytometry in comparison with histologic measurements in malignant melanomas. Rec. Res. Cancer Res. 1994: 39; 195-204.
3. Stolz W, Vogt T, Landthaler M, Abmayr W. Computerized quantitative dermatopathology. In Stoecker W ed. Computer applications in dermatology. New York: Igaku-Shoin, 1993; 140-162.
4. Stolz W, Abmayr W, Schmoeckel C, Landthaler M, Massoudy P, Braun-Falco O. Ultrastructural discrimination between malignant melanomas and benign nevocytic nevi using high-resolution image and multivariate analysis. J. Invest. Dermatol. 1991: 97; 903-910.
5. Ronan SG, Han MC, Das Gupta TK. Histologic prognostic indicators in cutaneous melanoma. Semin. Oncol. 1988: 15; 558-565.
6. Buettner P, Garbe C, Bertz J et al. Primary cutaneous melanoma. Optimized cutoff points of tumor thickness and importance of Clark's level for prognostic classification. Cancer 1995: 75; 2499-2506.
7. Soong SJ, Shaw HM, Balch CM, McCarthy WH, Urist MM, Lee JY. Predicting survival and recurrence in localized melanoma: a multivariate approach. World J. Surg. 1992: 16; 191-195.
8. Rivers JK, McCarthy SW, Shaw HM et al. Patients with thick melanomas surviving at least 10 years: histological, cytometric and HLA analyses. Histopathol 1991: 18; 339-346.
9. Ball NJ, Golitz LE. Melanocytic nevi with focal atypical epithelioid cell components: a review of seventy-three cases. J. Am. Acad. Dermatol. 1994: 30; 724-729.
10. Eeles RA, Warren W, Knee G et al. Constitutional mutation in exon 8 of the p53 gene in a patient with multiple primary tumours: molecular and immunohistochemical findings. Oncogene 1993: 8; 1269-1276.
11. Basset-Seguin N, Moles JP, Mils V, Dereure O, Guilhou JJ. TP53 tumor suppressor gene and skin carcinogenesis. J. Invest. Dermatol. 1994: 103; 102-106.
12. Rhim KJ, Hong SI, Hong WS, Lee SY, Lee DS, Jang JJ. Aberrant expression of p53 gene product in malignant melanoma. J. Korean Med. Sci. 1994: 9; 376-81.
13. Barnhill RL, Castresana JS, Rubio MP, Martin MT, Idoate M, Vazquez JJ, Thor AD. p53 expression in cutaneous malignant melanoma: an immunohistochemical study of 87 cases of primary, recurrent, and metastatic melanoma. Mod. Pathol. 1994: 7; 533-535.
14. Korabiowska M, Brinck U, Hoenig JF, et al. Significance of P-53 antigen in malignant melanomas and naevi of the head and neck area. Anticancer Res. 1995: 15; 885-889.
15. Platz A, Ringborg U, Grafstrom E, Hoog A, Lagerlof B. Immunohistochemical analysis of the N-ras p21 and the p53 proteins in naevi, primary tumours and metastases of human cutaneous malignant melanoma: increased immunopositivity in hereditary melanoma. Melanoma Res. 1995: 5; 101-106.
16. Sparrow LE, Soong R, Dawkins HJ, Iacopetta BJ, Heenan PJ. p53 gene mutation and expression in naevi and melanomas. Melanoma Res. 1995: 5; 93-100.
17. Yamamoto M, Takahashi H, Saitoh K, Horikoshi T, Takahashi M. Expression of the p53 protein in malignant melanomas as a prognostic indicator. Arch. Dermatol. Res. 1995: 287; 146-151.
18. Florenes VA, Holm R, Fodstad O. Accumulation of p53 protein in human malignant melanoma. Relationship to clinical outcome. Melanoma Res. 1995: 5; 183-187.
19. McCormick D, Chong H, Hobbs C, Datta C. Detection of the ki-67 antigen in fixed and wax-embedded sections with the monoclonal antibody MIB1. Histopathol. 1993: 22; 355-360.
20. Gerdes J, Lemke H, Wacker HH, Schwa U, Stein H. Cell cycle analysis of a cell-proliferation-associated human nuclear antigen defined by the monoclonal antibody ki-67. Immunol. 1984: 133; 1710-1715.
21. Scott RJ, Hall PA, Haldane JS, Van Noorden S, Price Y, Lane DP, Wright NA. A comparison of immunohistochemical markers of cell proliferation with experimentally determined growth fraction. J. Pathol. 1991: 165; 173-178.
22. Ramsey JA, From L, Iscoe NA, Kahn HJ. MIB-1 proliferative activity is a significant prognostic factor in primary thick cutaneous malignant melanomas. J. Invest. Dermatol. 1995: 105; 22-26.
23. Gundersen HJG, Jensen EB. Stereological estimation of the mean volume-weighted mean volume of arbitrary particles obseved on random sections. J. Microsc. 1985: 138; 127-142.
24. Binder M, Dolezal I, Wolff K, Pehamberger H. Stereologic estimation of volume-weighted mean nuclear volume as a predictor of prognosis in 'thin' malignant melanoma. J. Invest. Dermatol. 1992: 99; 180-183.
25. McGregor JM, Yu CC, Dublin EA, Barnes DM, Levison DA, MacDonald D M. p53 immunoreactivity in human malignant melanoma and dysplastic naevi. Br. J. Dermatol. 1993: 128; 606-611.
26. Evans AT, Blessing K, Orrell JM, Grant A. Mitotic indices, anti-PCNA, immunostaining, and AgNORs in thick cutaneous melanomas displaying paradoxical behaviour. J. Pathol. 1992: 168; 15-22.
27. Weiss J, Heine M, Arden KC, Korner B, Pilch H, Herbst RA, Jung EG. Mutation and expression of TP53 in malignant melanomas. Rec. Res. Cancer Res. 1995: 139; 137-54.
28. Stretch JR, Gatter KC, Ralfkiaer E, Lane DP, Harris AL. Expression of mutant p53 in melanoma. Cancer Res. 1991: 51; 5976-5979.
29. Akslen LA, Morkve O. Expression of p53 protein in cutaneous melanoma. Int. J. Cancer 1992: 52; 13-16.